BioSpace News Archive

Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its first quarter of 2022 ended March 31, 2022, after the market closes on Monday, May 9th 2022, and will hold a conference call to discuss its financial results at 2:00 p.m.

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics, announced that the company will issue its first quarter 2022 financial results after the close of market on Monday, May 16, 2022.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter financial results on Thursday, May 5, 2022.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that it will provide a corporate update and report financial results for the first quarter 2022 on Monday, May 9, 2022, after the U.S. financial markets close.

Veracyte, Inc. (Nasdaq: VCYT) announced today that an updated clinical practice guideline highlights the role of the Envisia Genomic Classifier in the diagnosis of idiopathic pulmonary fibrosis (IPF).

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the presentation of three abstracts featuring potential first-in-class radioenhancer NBTXR3 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7.

Alaunos Therapeutics, Inc. announced a poster presentation highlighting the Company’s membrane-bound interleukin-15 program as a potentially potent cell therapy targeting hotspot mutations expressed in solid tumors at the 25th Annual Meeting of the American Society of Gene and Cell Therapy being held in Washington, D.C. and virtually May 16-19, 2022.

Lyell Immunopharma, Inc. announced that two abstracts have been accepted for poster presentations at the 25th Annual Meeting of the American Society of Gene & Cell Therapy, scheduled for May 16 - May 19, 2022, in Washington, DC.

NeuBase Therapeutics, Inc. announced two abstracts have been accepted for presentation at the American Society of Gene and Cell Therapy 25th Annual Meeting, taking place virtually and in person in Washington, D.C., May 16-19, 2022.

Applied Genetic Technologies Corporation (Nasdaq: AGTC), today announced preclinical data presented at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) that expands the potential utility of its gene therapy platform to address neurogenerative diseases, such as frontotemporal dementia, and to demonstrate robust gene expression using hybrid dual AAV vectors.